TalkSooner and Baldwin Community School collaborate on youth vaping education

Sep.02.2022
TalkSooner and Baldwin Community School collaborate on youth vaping education
TalkSooner works with Michigan schools to educate parents and teens about the dangers and risks of electronic cigarette addiction.

As the number of teenagers vaping across the United States continues to rise, many school districts in West Michigan are taking measures to educate families about the dangers of addiction, including the Baldwin Community Schools.


TalkSooner is an organization dedicated to helping parents and teenagers understand the dangers of drug abuse. They are currently working in collaboration with Baldwin School to educate and facilitate discussions on the topic of teen use of electronic cigarettes.


This organization is a cooperative organization between Allegan County, Berrien County, Kent County, Muskegon County, and Ottawa County in western Michigan. It is coordinated by the West Michigan Shoreline Regional Development Commission (now known as the West Michigan Shoreline Regional Entity).


Recently, the organization partnered with the Baldwin Community School to launch a new education tool that will serve those who can provide information on e-cigarette use for teenagers.


This vehicle made its debut in the area on August 24th. The car displays information in English on one side and in Spanish on the other side through TalkSooner.


According to data from the 2018 National Youth Tobacco Survey (NYTS), the use of electronic cigarettes among current middle and high school students increased by 48% between 2017 and 2018. As of 2018, over 3.6 million children are currently using electronic cigarettes.


Griffin stated, "If you look at smoking, we almost didn't see the number of people smoking in the 50s and 60s because we not only had prevention, but education," Griffin said. "We now know smoking brings harm and can change our lives. We hope to ensure that we take the same measures for children who start vaping at 13 or 14 years old, to catch and quit this habit early or at least make them aware of the dangers that come with it.


On June 4, 2019, Governor Gretchen Whitmer signed Senate Bills 106 and 155, prohibiting the sale and possession of electronic cigarettes to anyone under the age of 18. In December of the same year, federal legislation was signed, raising the legal age to purchase or use tobacco products, including e-cigarettes, to 21. Despite these measures, many remain skeptical of the number of young students still using e-cigarettes.


Griffin has seen firsthand how difficult it is for parents to talk to teenagers about using e-cigarettes after her own child used them. "Preventative education seems to be the most important, not just for your physical health, but also for your mental and overall well-being," she said. "Even in the most educated households, there is still susceptibility to the pressures of e-cigarettes and such. I always encourage parents to have open conversations with their children, discussing their own struggles or choices made by young people. I also suggest trying to find out why they are interested in e-cigarettes or the root cause of their decision to use them.


In September 2018, the US Food and Drug Administration (FDA) sent over 1,300 warning letters and civil monetary penalties to retailers illegally selling e-cigarette products to minors, with the majority being blu, JUUL, Logic, MarkTen XL, and Vuse; this marked the FDA's largest coordinated enforcement effort to date.


According to the Centers for Disease Control and Prevention, some e-cigarette products have labels that do not disclose that they contain nicotine, while some e-cigarette liquids marketed as containing 0% nicotine have been found to contain nicotine.


Using nicotine during adolescence can damage the parts of the brain that control attention, learning, emotions, and impulse control, and may also impair brain development in teenagers. This damage can persist into the mid-20s.


Statement


This article is compiled from third-party information and is intended for industry communication and learning purposes only.


This article does not reflect the views of 2FIRSTS and we cannot verify the accuracy or truthfulness of its contents. The compilation of this article is only intended for industry-related research and exchange.


Due to limitations in the level of translation, the translated article may not express exactly the same meaning as the original. Please refer to the original text for accuracy.


2FIRSTS fully aligns its statements and position with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or international issues.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Zhang Xiaotang Appointed Deputy Director of China’s Tobacco Regulator, Adding Another Finance-Background Official to Top Leadership
Zhang Xiaotang Appointed Deputy Director of China’s Tobacco Regulator, Adding Another Finance-Background Official to Top Leadership
China’s State Council has appointed Zhang Xiaotang as deputy director of the State Tobacco Monopoly Administration, with the regulator’s official website now listing him as a Party leadership group member and deputy director. Zhang previously led Hebei China Tobacco and earlier headed the STMA’s finance and audit department. His appointment follows the elevation earlier this year of former tax official Yao Laiying to head the STMA, adding another senior official with a strong fiscal or financial-management background to China Tobacco’s top leadership in 2026.
News
Sep.20
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
PMI Pushes Smoke-Free Business in Latin America as Argentina Lifts Heated Tobacco Ban, Mexico City Share Tops 7%
PMI Pushes Smoke-Free Business in Latin America as Argentina Lifts Heated Tobacco Ban, Mexico City Share Tops 7%
Philip Morris International (PMI) showcased IQOS heated tobacco systems and nicotine pouch products at Technovation 2026 in Buenos Aires on October 7–8, presenting research on consumer attitudes, regulatory developments and illicit cigarette trade across Latin America. PMI Chief Global Growth Officer Stefano Volpetti said smoke-free products accounted for more than 7% of the Mexico City market. Argentina repealed its heated tobacco ban in May 2026 and introduced registration requirements for tobacco and nicotine products, while local media reported nicotine pouch sales in Mendoza. A PMI-commissioned survey found that only 8% of respondents across four Latin American countries were familiar with nicotine pouches. A separate KPMG study estimated illicit cigarette consumption at 77 billion sticks across 11 markets in Latin America and Canada in 2025.
PMI
Oct.13
Beyond IQOS ILUMA, PMI Expands Lower-Priced BONDS Heated Tobacco Platform: Seven Markets Added in Q3, With Rollouts in Japan, Europe and North Africa
Beyond IQOS ILUMA, PMI Expands Lower-Priced BONDS Heated Tobacco Platform: Seven Markets Added in Q3, With Rollouts in Japan, Europe and North Africa
Philip Morris International (PMI) is expanding the international footprint of BONDS by IQOS, its lower-priced heated tobacco platform. The company's third-quarter 2026 SEC filing shows that BONDS devices and BLENDS tobacco sticks were available in 15 markets at the end of September, up from eight at the end of June. In November, PMI announced plans to extend sales from three to 17 Japanese prefectures and introduced BONDS in Spain and Morocco. The platform uses ROUNDHEAT external heating technology and proprietary tobacco sticks, separate from the IQOS ILUMA system. In Japan, BONDS retails for ¥2,980, approximately 25% below ILUMA i ONE, while BLENDS costs ¥570 per pack. PMI management says BONDS targets cigarette smokers who have not adopted heated tobacco. Separate sales and revenue figures remain undisclosed.
company
Nov.06
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22